Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) Shares Outstanding (Weighted Average) (2021 - 2025)

Historic Shares Outstanding (Weighted Average) for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to $9.5 million.

  • Verrica Pharmaceuticals' Shares Outstanding (Weighted Average) rose 10275.6% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year increase of 10275.6%. This contributed to the annual value of $51.8 million for FY2024, which is 1425.99% up from last year.
  • Per Verrica Pharmaceuticals' latest filing, its Shares Outstanding (Weighted Average) stood at $9.5 million for Q3 2025, which was up 10275.6% from $9.5 million recorded in Q2 2025.
  • In the past 5 years, Verrica Pharmaceuticals' Shares Outstanding (Weighted Average) registered a high of $94.8 million during Q1 2025, and its lowest value of $4.7 million during Q2 2024.
  • For the 5-year period, Verrica Pharmaceuticals' Shares Outstanding (Weighted Average) averaged around $33.6 million, with its median value being $27.7 million (2021).
  • Per our database at Business Quant, Verrica Pharmaceuticals' Shares Outstanding (Weighted Average) tumbled by 8987.25% in 2024 and then surged by 10403.42% in 2025.
  • Verrica Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $27.0 million in 2021, then rose by 26.32% to $34.2 million in 2022, then surged by 32.72% to $45.3 million in 2023, then rose by 14.26% to $51.8 million in 2024, then plummeted by 81.68% to $9.5 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $9.5 million for Q3 2025, versus $9.5 million for Q2 2025 and $94.8 million for Q1 2025.